New analysis shows survival benefit of Novartis' Kisqali

27th May 2020 Uncategorised 0

In patients with liver metastases, Kisqali combination therapy cut the risk of death by 47% and 37% in two trials

More: New analysis shows survival benefit of Novartis' Kisqali
Source: News